Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction
Ende Zhao,Tomasz Maj,Ilona Kryczek,Wei Li,Ke Wu,Lili Zhao,Shuang Wei,Joel Crespo,Shanshan Wan,Linda Vatan,Wojciech Szeliga,Irene Shao,Yin Wang,Yan Liu,Sooryanarayana Varambally,Arul M Chinnaiyan,Theodore H Welling,Victor Marquez,Jan Kotarski,Hongbo Wang,Zehua Wang,Yi Zhang,Rebecca Liu,Guobin Wang,Weiping Zou
DOI: https://doi.org/10.1038/ni.3313
Abstract:Aerobic glycolysis regulates T cell function. However, whether and how primary cancer alters T cell glycolytic metabolism and affects tumor immunity in cancer patients remains a question. Here we found that ovarian cancers imposed glucose restriction on T cells and dampened their function via maintaining high expression of microRNAs miR-101 and miR-26a, which constrained expression of the methyltransferase EZH2. EZH2 activated the Notch pathway by suppressing Notch repressors Numb and Fbxw7 via trimethylation of histone H3 at Lys27 and, consequently, stimulated T cell polyfunctional cytokine expression and promoted their survival via Bcl-2 signaling. Moreover, small hairpin RNA-mediated knockdown of human EZH2 in T cells elicited poor antitumor immunity. EZH2(+)CD8(+) T cells were associated with improved survival in patients. Together, these data unveil a metabolic target and mechanism of cancer immune evasion.